Sign up to save your podcasts
Or
Share Advances in cell therapies for Parkinson’s, GLP-1 agonists and dementia risk, FDA accelerated approvals for neurology drugs
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Advances in cell therapies for Parkinson’s, GLP-1 agonists and dementia risk, FDA accelerated approvals for neurology drugs
In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about early studies finding dopamine cellular therapies were safe and tolerable for patients with Parkinson’s, use of GLP-1 agonists were associated with reduced dementia risks, and the FDA use of accelerated approvals for several neurology drugs are under scrutiny.
View all episodes
By American Academy of Neurology
4.7
1919 ratings
In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about early studies finding dopamine cellular therapies were safe and tolerable for patients with Parkinson’s, use of GLP-1 agonists were associated with reduced dementia risks, and the FDA use of accelerated approvals for several neurology drugs are under scrutiny.
More shows like Neurology Today in 5
View all
Neurology® Podcast
290 Listeners
NEJM This Week
322 Listeners
Practical Neurology Podcast
49 Listeners
This Week in Cardiology
874 Listeners
JAMA Clinical Reviews
504 Listeners
JAMA Neurology Author Interviews
13 Listeners
JAMA Medical News
87 Listeners
BMJ Best Practice Podcast
24 Listeners
The Clinical Problem Solvers
516 Listeners
Neurology Minute
131 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
360 Listeners
Neurology Exam Prep Podcast
183 Listeners
The Curious Clinicians
367 Listeners
The Lancet Neurology in conversation with
5 Listeners
Continuum Audio
79 Listeners